Nonetheless, both the AR and Tip60 are undeniably master regulators of the metabolic network in prostate cancer and they continue to constitute potential avenues for novel therapeutic options in androgen-sensitive prostate cancer. This evidence concerns the gene KAT5 and prostate carcinoma.